Please login to the form below

Not currently logged in
Email:
Password:

MabThera

This page shows the latest MabThera news and features for those working in and with pharma, biotech and healthcare.

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera.

Latest news

  • MSD launches EU’s first biosimilar Herceptin in UK MSD launches EU’s first biosimilar Herceptin in UK

    Roche has particularly high exposure to biosimilar erosion in the coming years in its first-generation antibody products - with Avastin (bevacizumab) and MabThera (rituximab) also under threat along with Herceptin - but

  • NICE backs Roche’s Gazyvaro after initial rejection NICE backs Roche’s Gazyvaro after initial rejection

    clinical profile justified premium pricing over Mabthera (rituximab), Roche’s older drug for the FL indication. ... Like MabThera, Gazyvaro targets the CD20 receptor but has been designed with sugar molecule side chains that improve its therapeutic and

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    Novartis’unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab).

  • Novartis doubles down on biosimilars with Biocon alliance Novartis doubles down on biosimilars with Biocon alliance

    In the last couple of years it has picked up approvals for Rixathon - a biosimilar of Roche’s cancer and arthritis drug MabThera (rituximab) - as well as its Erelzi version of

  • Roche's Actemra/RoActemra receives new European approval Roche's Actemra/RoActemra receives new European approval

    Horning said: “By challenging our own MabThera medicine head-to-head, we have been able to set a new standard of care for people with follicular lymphoma. ... with follicular lymphoma who did not respond to or who progressed during or up to six months

More from news
Approximately 15 fully matching, plus 103 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Humira remains at the top, but Celgene’s Revlimid has jumped ahead of Roche’s Avastin, MabThera and Herceptin.

  • Deal Watch November 2016 Deal Watch November 2016

    We are starting to see more deals covering biosimilars and this month Poland-based Mabion signed a supply and commercialisation agreement with Mylan for a biosimilar of Roche's ... competitors. The patents covering MabThera/Rituxan expired in Europe in

  • Pharma deals in June 2015 Pharma deals in June 2015

    Roche has two products approved in Europe, Herceptin SC and MabThera SC, and Baxter has HyQvia approved in the US and EU, which utilise the Halozyme approach. ... Herceptin SC and MabThera SC can be administered in approximately 5 minutes by sc injection

  • Russian innovation at the crossroads Russian innovation at the crossroads

    For example, in autumn 2014, BIOCAD fully pushed out Roche's Mabthera (rituximab) from public procurement.

  • Pharma deals during December 2014 Pharma deals during December 2014

    Subcutaneous formulations of both MabThera and Herceptin based on the Halozyme technology have been launched by Roche.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Sanofi hires David Loew from Roche Sanofi hires David Loew from Roche

    He gradually rose up the ranks at Roche, holding senior marketing positions such as life cycle leader for both MabThera and Xeloda, head of oncology and chief marketing officer, before taking

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The Biosimilar Challenge

    Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).

  • Biosimilars: Getting the flock to market

    The greatest attraction, naturally, is high-revenue anti-TNF agents like MabThera (rituximab) and Humira (adalimumab), for many years the world's most valuable drug.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Life Brands Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics